Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

TPEX/4162 stock hub

TPEX/4162 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

TPEX/4162is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

8.3B

Taipei Exchange

Market data

Live price

Current market quote for this ticker.

Current price

TPEX/4162

In the news

Latest news · TPEX/4162

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E20.9

P25 12P50 15.5P75 22.5

Trailing P/E21.5

P25 14.4P50 18P75 31.9

ROE7.5

P25 -16.2P50 0.3P75 9.8

ROIC141.5

P25 -11.7P50 -0.2P75 8.8

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All TPEX/4162 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

240

Groups with data

Currency

TWD

Showing 240 of 240 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Taiwan
Country code	TW
Employees	45
Employees Change	1%
Employees Change Percent	2.27
Enterprise value	TWD 3.6B
Exchange	Taipei Exchange
Financial currency	TWD
First seen	2026-05-10
Industry	Biotechnology
Isin	TW0004162003
Last refreshed	2026-05-10
Market cap	TWD 8.3B
Price	TWD 57.8
Price currency	TWD
Rev Per Employee	20,253,688.89x
Sector	Healthcare
Sic	2836
Symbol	tpex/4162
Website	https://www.pharmaengine.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	4.67%
EV Earnings	9.36x
EV/EBIT	8.53x
EV/EBITDA	8.33x
EV/FCF	2.1x
EV/Sales	3.98x
FCF yield	20.79%
Forward P/E	20.94x
P/B ratio	1.69x
P/E ratio	21.49x
P/S ratio	9.11x
PE Ratio10 Y	75.8x
PE Ratio3 Y	31.32x
PE Ratio5 Y	30.16x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	46.68%
EBITDA Margin	46.87%
FCF margin	189.44%
Gross margin	94.31%
Gross Profit	TWD 859.6M
Gross Profit Growth	-65.28%
Gross Profit Growth Q	-85.58%
Gross Profit Growth3 Y	12.44%
Gross Profit Growth5 Y	-3.34%
Net Income	TWD 387.6M
Net Income Growth	-77.86%
Net Income Growth Q	-90.76%
Net Income Growth Years	0%
Net Income Growth3 Y	6.74%
Net Income Growth5 Y	-8.5%
Pretax Margin	55.88%
Profit Margin	42.53%
Profit Per Employee	TWD 8.6M
Profitable Years	12
ROA	4.84
Roa5y	9.06
ROCE	8.58
ROE	7.51
Roe5y	14.26
ROIC	141.5
Roic5y	102.7

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-6.94%
Cagr1y	-28.62%
Cagr3y	-13.65%
Cagr5y	0.58%
Div CAGR10	13.67%
Div CAGR3	44.22%
Div CAGR5	18.81%
EPS Growth	-77.9
EPS Growth Q	-90.75
EPS Growth Years	0
EPS Growth3 Y	6.61
EPS Growth5 Y	-8.26
FCF Growth	278.7%
FCF Growth Q	6.08%
FCF Growth3 Y	105.63%
FCF Growth5 Y	92.83%
OCF Growth	278.09%
OCF Growth Q	5.99%
OCF Growth10 Y	14.45%
OCF Growth3 Y	104.47%
OCF Growth5 Y	92.83%
Revenue Growth	-63.88x
Revenue Growth Q	-84.83x
Revenue Growth Years	0x
Revenue Growth3 Y	11.68x
Revenue Growth5 Y	-2.9x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	TWD 0.17
Assets	TWD 5.1B
Cash	TWD 4.7B
Current Assets	TWD 5.1B
Current Liabilities	TWD 187.1M
Debt	TWD 42.1M
Debt EBITDA	TWD 0.1
Debt Equity	TWD 0.01
Debt FCF	TWD 0.02
Equity	TWD 4.9B
Interest Coverage	3,060.9
Liabilities	TWD 221.6M
Long Term Assets	TWD 62.7M
Long Term Liabilities	TWD 34.4M
Net Cash	TWD 4.7B
Net Cash By Market Cap	TWD 56.29
Net Cash Growth	21.31%
Net Debt EBITDA	TWD -10.94
Net Debt Equity	TWD -0.95
Net Debt FCF	TWD -2.71
Tangible Book Value	TWD 4.9B
Tangible Book Value Per Share	TWD 34.28
WACC	5.18

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	27.17
Inventory Turnover	1.52
Net Working Capital	TWD 189.5M
Quick ratio	26.9
Working Capital	TWD 4.9B
Working Capital Turnover	TWD 0.18

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.01%
Dividend Growth	300%
Dividend Growth Years	1%
Dividend per share	TWD 2
Dividend Years	11
Dividend Yield	3.46%
Ex Div Date	2025-08-13
Last Dividend	TWD 6
Payout Frequency	Annual
Payout Ratio	222.35%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-51.28%
1Y total return	-28.6%
200-day SMA	67.37
3Y total return	-35.62%
50-day SMA	58.4
50-day SMA vs 200-day SMA	50under200
5Y total return	2.93%
All Time High	246.6
All Time High Change	-76.56%
All Time High Date	2014-05-28
All Time Low	33.1
All Time Low Change	74.62%
All Time Low Date	2020-03-23
ATR	1.39
Beta	0.17
Beta1y	0.41
Beta2y	0.5
Ch YTD	-17.9
High	59.2
High52	93.7
High52 Date	2025-05-23
High52ch	-38.31%
Low	57.7
Low52	53
Low52 Date	2026-04-27
Low52ch	9.06%
Ma50ch	-1.03%
Price vs 200-day SMA	-14.2%
RSI	53.18
RSI Monthly	35.68
RSI Weekly	36.89
Sharpe ratio	-1.22x
Sortino ratio	-1.5
Total Return	3.45%
Tr YTD	-17.9
Tr1m	-1.2%
Tr1w	4.52%
Tr3m	-7.52%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	TWD 425.5M
Operating Income Growth	-79.28
Operating Income Growth Q	-93.11
Operating Income Growth3 Y	14.59
Operating Income Growth5 Y	-12.08
Operating margin	46.68

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	93,450,822%
Net Borrowing	-8,445,000
Shares Insiders	1.23%
Shares Institutions	5.8%
Shares Out	143,677,640
Shares Qo Q	0.21%
Shares Yo Y	0.01%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	TWD 1.7B
Average Volume	406,777.6x
Bv Per Share	34.28
CAPEX	TWD -280,000
Ch10y	-62.17
Ch1m	-1.2
Ch1w	4.52
Ch1y	-34.09
Ch3m	-7.52
Ch3y	-43.05
Ch5y	-15.5
Ch6m	-15
Change	0%
Change From Open	-0.69
Close	57.8
Days Gap	0.69
Depreciation Amortization	1,751,000
Dollar Volume	27,968,379.6
Earnings Date	2026-05-12
EBIT	TWD 425.5M
EBITDA	TWD 427.2M
EPS	TWD 2.69
F Score	5
FCF	TWD 1.7B
FCF EV Yield	47.57x
FCF Per Share	TWD 12.02
Financing CF	-870,369,000
Fiscal Year End	December
Founded	2,002
Graham Number	45.55304
Graham Upside	-21.19
Income Tax	TWD 121.7M
Investing CF	-266,655,000
Is Primary Listing	1
Last Earnings Date	2025-11-12
Last Report Date	2025-12-31
Last Split Date	2017-07-26
Last Split Type	Forward
Lynch Fair Value	TWD 13.45
Lynch Upside	-76.73
Ma150	65.89
Ma150ch	-12.28%
Ma20	56.8
Ma20ch	1.76%
Net CF	589,826,000
Next Earnings Date	2026-05-12
Open	58.2
P FCF Ratio	4.81
P OCF Ratio	4.81
Payment Date	2025-08-29
Position In Range	6.67
Ppne	44,679,000
Price Date	2026-05-08
Price EBITDA	TWD 19.44
Ptbv Ratio	1.69
Relative Volume	1.2x
Revenue	911,416,000x
SBC By Revenue	0.04x
Share Based Comp	403,000
Tax By Revenue	13.35x
Tax Rate	23.89%
Tr6m	-15%
Volume	483,882
Z Score	34.37

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

TPEX/4162 dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+3.5%

$2.00 annual per share

Payout ratio

+222.4%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+18.8%

1 consecutive years of growth

Total shareholder yield

+3.5%

Next ex-dividend date: 2025-08-13

Performance

TPEX/4162 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns TPEX/4162?

Insider, institutional, and short-interest positioning.

Institutional ownership

+5.8%

Share of float held by funds and institutions

Insider ownership

+1.2%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+0.0%

Negative means the company is buying back shares.

Technical

TPEX/4162 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

53.2

Neutral momentum band

Price vs 200-day MA

-14.2%

50/200-day relationship not available

Beta (5Y)

0.17

Less volatile than the market

Sharpe ratio

-1.22

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About TPEX/4162

Hub-level FAQ points readers to the deeper analysis pages.

What is the current tpex/4162 stock rating?

tpex/4162 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full tpex/4162 analysis?

The full report lives at /stocks/tpex/4162/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for tpex/4162?

The latest report frames tpex/4162 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the tpex/4162 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.